Navigation Links
Personalized antiplatelet treatment improves outcome after PCI
Date:8/28/2012

The findings were presented by Dr Jolanta Siller-Matula from Medical University of Vienna.

Standard antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) consists of a dual antiplatelet therapy with aspirin and an ADP receptor inhibitor such as clopidogrel.

But measurements of platelet aggregation in clopidogrel treated patients indicate that one patient in four is a non-responder to the drug. Such non-responsiveness is attributed to clopidogrel's extensive hepatic metabolism, polymorphisms of metabolising enzymes and drug-drug interactions, with additional contributions coming from clinical variables such as diabetes, body mass index, acute coronary syndrome, ejection fraction and renal failure. Multiple studies have demonstrated a clear association between non-responsiveness to clopidogrel and adverse clinical events. The strongest relationship was found between poor clopidogrel response and short term events, particularly stent thrombosis.

Personalized antiplatelet treatment involves choosing a therapy based on the results of platelet function testing, a measurement which shows how effective an antiplatelet drug such as clopidogrel is at inhibiting platelet aggregation. Non-responders to the drug can be given a higher dose of clopidogrel or an alternate antiplatelet therapy such as the more potent platelet inhibitors prasugrel or ticagrelor. Personalized antiplatelet treatment only in clopidogrel non-responders would be a therapeutic strategy reaching two goals: increase of clinical efficacy only in patients who are at increased risk for ischemic events without exposing patients with a proper clopidogrel response to bleedings with use of very potent platelet antagonists.

In the MADONNA study (Multiple electrode Aggregometry in patients receiving Dual antiplatelet therapy tO guide treatmeNt with Novel platelet Antagonists), Austrian investigators led by Dr Jolanta Siller-Matula from the Medical University of Vienna and Professor Gnter Christ from Kaiser Franz Josef Hospital in Vienna, investigated whether individualized treatment with platelet inhibitors according to the results of whole blood aggregometry improves clinical outcomes in patients undergoing percutaneous coronary intervention.

A total of 798 patients underwent platelet testing with whole blood aggregometry using the multiple electrode aggregometry (MEA) technique, which allowed patients to be classified as clopidogrel responders or non-responders. Patients were then allocated to the guided group or the non-guided group. In the guided group (n=403) clopidogrel non-responders (26%) received up to four loading doses of clopidogrel or after prasugrel became available, the more potent platelet inhibitor prasugrel. In the non-guided group (n=395) clopidogrel non-responders (25%) were further treated with the standard treatment consisting of clopidogrel and aspirin.

Results showed that patients in the non-guided group were at a 7.9-fold higher risk to develop stent thrombosis compared to the patients in the guided group (1.9% versus 0.2%; p=0.027). Furthermore acute coronary syndrome occurred in 0% of patients in the guided group versus 2.5% in the non-guided group (p=0.001). There were no differences between the two groups in the rates of cardiac death or major bleeding.

"Introducing clopidogrel testing into clinical practice might be feasible: it involves a blood sample and takes ten minutes to get a result," said Dr Siller-Matula, first author of the study. "Providing individualized treatment based on the results of MEA instead of using novel antiplatelet drugs in each patient would save costs of drug therapy of about 410 per patient each year. As individualized antiplatelet therapy seems to be cost-effective, it might be of interest to health authorities."

"Physicians would never adjust doses of antihypertensive drugs without knowing blood pressures; statins, without knowing cholesterol levels; or antidiabetic drugs without knowing the HbA1C levels," she added. "So why are we still treating our patients with platelet inhibitors without being aware of levels of platelet inhibition?"


'/>"/>

Contact: European Society of Cardiology
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. New method may allow personalized clinical trial for cancer therapies
2. University of Pennsylvania and Novartis form alliance to expand use of personalized T cell cancer therapy
3. A new genre of diagnostic tests for the era of personalized medicine
4. Personalized Blood Pressure Therapy May Help Diabetics
5. Little Evidence on Value of Treatments for Autism: Report
6. Reducing the side effects of treatment for prostate cancer
7. Little evidence supports autism treatment options in adolescents
8. pH-sensitive liposomal cisplatin improves peritoneal carcinomatosis treatment without side-effects
9. Study: Clot removal devices successful tools for acute ischemic stroke treatment
10. Circadian clock research may enable designer plants, and cancer and diabetes treatments
11. NIH launches trial to evaluate anti-inflammatory treatment for preventing heart attacks, strokes, and cardiovascular deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... 26, 2017 , ... New patients with missing teeth in Fitchburg, ... a referral. Dr. Cotey is a trusted dentist who has placed many dental implants ... Patients with missing teeth in Fitchburg, WI, are encouraged to find out if they ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology: